Page last updated: 2024-10-24

carmustine and Antibody Deficiency Syndrome

carmustine has been researched along with Antibody Deficiency Syndrome in 2 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sklar, CA1
Kim, TH1
Ramsay, NK1
Maze, R1
Kapur, R1
Kelley, MR1
Hansen, WK1
Oh, SY1
Williams, DA1

Other Studies

2 other studies available for carmustine and Antibody Deficiency Syndrome

ArticleYear
Thyroid dysfunction among long-term survivors of bone marrow transplantation.
    The American journal of medicine, 1982, Volume: 73, Issue:5

    Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Carmustine; Child; Child, Preschoo

1982
Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA.
    Journal of immunology (Baltimore, Md. : 1950), 1997, Jan-15, Volume: 158, Issue:2

    Topics: Animals; Bone Marrow Transplantation; Carmustine; DNA, Complementary; Hematopoietic Stem Cells; Immu

1997